Determination Method Validation of Bioactivity of Adalimumab Monoclonal Antibody by Apoptosis Assay

Main Article Content

Jiradej Patchim
Sompong Sapsutthipas
Saiwarul Jadoonkittinan

Abstract

Background: Adalimumab is an immunosuppressive drug that works by blocking tumor necrosis factor-alpha, commonly used to treat autoimmune inflammatory diseases. The structure of adalimumab is a fully human recombinant immunoglobulin G1 (IgG1) monoclonal antibody that represents significant specificity for these diseases. At present, the various brand names for adalimumab are imported and registered in Thailand. Consequently, an efficient quality control system of the products, including physicochemical properties and biological activity must be controlled before distribution to the market. Nevertheless, potency assays are not available in the international monographs. As a result, potency analysis is essential for the development and standardisation of methods aimed at increasing laboratory capacity for quality control in a wide range of adalimumab.


Objectives: To verify the validity of biological activity in adalimumab by apoptosis technique using U-937 cells as target cells to be used to standardize the method for laboratory quality control in Thailand.


Methods: This was an experimental study from October 2020 to August 2021 that for method validation of the biological activity of adalimuab by apoptosis on parameters including specificity, precision, robustness, accuracy, linearity, and range by using international standard against the potency of adalimumab.


Results: The results of potency assay demonstrated that this method was specific to the target cells as U-937 cells of adalimumab. Linearity and range showed an R2 = 0.996 in a potency range of 50-100% of relative potency. The %GCV of repeatability and intermediate precision differed by analysts and days but did not exceed five. The percent recovery of accuracy ranged from 80 to 125%. In addition, this method exhibited good robustness as the range of %GCV was from 5.74 to 9.57, with no statistically significant differences (p>0.05), and the relative potency assay ranged from 80 to 125% compared to the international reference standard. 


Conclusions: The determination of biological activity for adalimumab by the apoptosis method using U-937 cells as target cells was found to be suitable and reliable for laboratory quality control for both originator and biosimilars of adalimumab.

Article Details

How to Cite
1.
Patchim J, Sapsutthipas S, Jadoonkittinan S. Determination Method Validation of Bioactivity of Adalimumab Monoclonal Antibody by Apoptosis Assay. TFDJ [Internet]. 2023 Mar. 22 [cited 2024 Apr. 13];30(1):32-46. Available from: https://he01.tci-thaijo.org/index.php/fdajournal/article/view/262458
Section
Research Article
Author Biographies

Jiradej Patchim, 1Institute of Biological Products, Department of Medical Sciences, Nonthaburi, Thailand

Institute of Biological Products, Department of Medical Sciences, Tiwanon Road, Mueang District, Nonthaburi, 11000, Thailand

Sompong Sapsutthipas, Institute of Biological Products, Department of Medical Sciences, Nonthaburi, Thailand

Institute of Biological Products, Department of Medical Sciences, Tiwanon Road, Mueang District, Nonthaburi, 11000, Thailand

Saiwarul Jadoonkittinan, Institute of Biological Products, Department of Medical Sciences, Nonthaburi, Thailand

Institute of Biological Products, Department of Medical Sciences, Tiwanon Road, Mueang District, Nonthaburi, 11000, Thailand

References

ŽIGON-BRANC, Sara; BARLIČ, Ariana; JERAS, Matjaž. in vitro cell-based assays for potency testing of anti-TNF-α Biological Drugs. In: Cytokines. IntechOpen, 2019.

Focosi D., Maggi F., Pistello M., Boggi U., Scatena F. Immunosuppressive monoclonal antibodies: current and next generation. Clinical microbiology and infection 2011;17(12): 1759 - 68.

GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [Internet]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 12] Available from: https://gabionline.net/biosimilars/general/Biosimilars-of-adalimumab

WHO Expert Committee on Biological Standardization. Report on a Collaborative Study for Proposed Candidate 1st International Standard for Adalimumab. World Health Organization; WHO/BS/2019.2365.

สำนักยา สำนักงานคณะกรรมการอาหารและยา. คู่มือและหลักเกณฑ์การขึ้นทะเบียนตำรับยาชีววัตถุคล้ายคลึง (Biosimilars) [อินเทอร์เน็ต]. กรุงเทพฯ: อักษรกราฟฟิคแอนด์ดีไซน์; 2561 [เข้าถึงเมื่อ 23 ก.พ. 2563]. 125 หน้า. เข้าถึงได้จาก:http://www.fda.moph.go.th/sites/drug/Shared%20Documents/Biosimilars/Biosimilar.pdf

สุชาติ จองประเสริฐ. ยาชีววัตถุคล้ายคลึง (Biosimilars) ในบริบทสาธารณสุข. วารสารอาหารและยา 2557; 21(1): 9-14.

WHO Expert Committee on Biological Standardization. Annex 2: Guideline on evaluation of similar biotherapeutic products (SBPs). WHO technical report series No. 977. World Health Organization 2013: 51-89.

Yang H, Kim HJ, Zhang L, Strouse RJ, Schenerman M, Jiang X. Implementation of parallelism testing for four-parameter logistic model in bioassays. PDA Journal of Pharmaceutical Science and Technology 2012; 66(3): 262-69.

European Medicines Agency. ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. (CPMP/ICH/381/95) [Internet]. 1995 [cited 2021 June 19]. 15 p. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf

United States Pharmacopeia (2022). General Chapter, <1033> Biological Assay Validation. USP-NF. Rockville, MD: United States Pharmacopeia. DOI: https://doi.org/10.31003/USPNF_M912_01_01